Intellectual Property partner Thomas J. Campbell, Jr., recently authored the article “SCOTUS Takes on Scope of Enablement Inquiry in Amgen v. Sanofi: Implications for Pharma/ Biotech and Beyond,” published in IPWatchdog on November 13. In the article, Tom explains how the Supreme Court will take up a case asking the court to weigh in on whether the quality or quantity of experimentation dictates whether an invention is sufficiently enabled.

Click here to read the article.